Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint in Unresectable Desmoid Tumor
NCT03459469Phase 1Completed
- Sponsor
- Iterion Therapeutics
- Start
- Jul 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tegavivint in desmoid tumor, sponsored by Iterion Therapeutics. Primary endpoint: Safety and Tolerability at 12 Months. Started Jul 2018; status: completed.
02
Drugs
tegavivint
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT03459469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459469.